Endoscopic Ultrasound-Guided Hepaticogastrostomy With Plastic Stent Versus Metallic Stent for Malignant Biliary Obstruction: A Meta-Analysis.

Dig EndoscSep 30, 2026
Clinical ResearchGastroenterology

Hirofumi Yamazaki, Masahiro Itonaga, Ke Wan et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the efficacy and safety of plastic versus metal stents in endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) for malignant biliary obstruction. The analysis included six studies, revealing that the time to recurrent biliary obstruction (TRBO) was significantly longer for metal stents (hazard ratio 1.83; 95% CI 1.42-2.36) compared to plastic stents.

Key findings

  • Metal stents had a significantly longer TRBO than plastic stents (hazard ratio 1.83; 95% CI 1.42-2.36).
  • The adverse event rate was significantly higher in the metal stent group (OR 0.48; 95% CI 0.30-0.77).
  • Plastic stents had a higher recurrent biliary obstruction rate compared to metal stents (OR 1.75; 95% CI 1.06-2.88).
  • No significant differences were found in clinical success or re-intervention success rates.

Why it matters

Understanding the differences in outcomes between plastic and metal stents in EUS-HGS can guide clinicians in selecting the appropriate stent type for patients with malignant biliary obstruction, balancing efficacy and safety.

Source

PubMed · PMID 42806906

Published in Dig Endosc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.